Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.
2.

Characterization of oligomers induced by inverse agonists of CTLA-4.

Teft WA, Madrenas J.

Immunol Lett. 2008 Oct 30;120(1-2):29-36. doi: 10.1016/j.imlet.2008.06.005. Epub 2008 Jul 15.

PMID:
18634825
3.

Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation.

Darlington PJ, Kirchhof MG, Criado G, Sondhi J, Madrenas J.

J Immunol. 2005 Jul 15;175(2):996-1004.

4.
5.

CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.

Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, Baroja ML, Madrenas J.

J Immunol. 2000 Aug 1;165(3):1352-6.

6.

B7-independent inhibition of T cells by CTLA-4.

Chikuma S, Abbas AK, Bluestone JA.

J Immunol. 2005 Jul 1;175(1):177-81.

7.

Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist.

Fife BT, Griffin MD, Abbas AK, Locksley RM, Bluestone JA.

J Clin Invest. 2006 Aug;116(8):2252-61.

8.
9.

A theoretical framework for quantitative analysis of the molecular basis of costimulation.

Jansson A, Barnes E, Klenerman P, Harlén M, Sørensen P, Davis SJ, Nilsson P.

J Immunol. 2005 Aug 1;175(3):1575-85.

10.

An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice.

Loser K, Scherer A, Krummen MB, Varga G, Higuchi T, Schwarz T, Sharpe AH, Grabbe S, Bluestone JA, Beissert S.

J Immunol. 2005 May 1;174(9):5298-305.

11.

B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties.

Bhatia S, Edidin M, Almo SC, Nathenson SG.

Immunol Lett. 2006 Apr 15;104(1-2):70-5. Epub 2005 Dec 13. Review.

PMID:
16413062
12.

Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression.

Chuang E, Alegre ML, Duckett CS, Noel PJ, Vander Heiden MG, Thompson CB.

J Immunol. 1997 Jul 1;159(1):144-51.

PMID:
9200449
13.
14.

Tyrosine-mediated inhibitory signals contribute to CTLA-4 function in vivo.

Yi LA, Hajialiasgar S, Chuang E.

Int Immunol. 2004 Apr;16(4):539-47.

PMID:
15039384
15.

CTLA-4 lacking the cytoplasmic domain costimulates IL-2 production in T-cell hybridomas.

Hueber AJ, Matzkies FG, Rahmeh M, Manger B, Kalden JR, Nagel T.

Immunol Cell Biol. 2006 Feb;84(1):51-8.

PMID:
16405652
16.

TIRC7 inhibits T cell proliferation by modulation of CTLA-4 expression.

Bulwin GC, Heinemann T, Bugge V, Winter M, Lohan A, Schlawinsky M, Schulze A, Wälter S, Sabat R, Schülein R, Wiesner B, Veh RW, Löhler J, Blumberg RS, Volk HD, Utku N.

J Immunol. 2006 Nov 15;177(10):6833-41.

17.

Conversion of CTLA-4 from inhibitor to activator of T cells with a bispecific tandem single-chain Fv ligand.

Madrenas J, Chau LA, Teft WA, Wu PW, Jussif J, Kasaian M, Carreno BM, Ling V.

J Immunol. 2004 May 15;172(10):5948-56.

18.

Cutting edge: tyrosine-independent transmission of inhibitory signals by CTLA-4.

Cinek T, Sadra A, Imboden JB.

J Immunol. 2000 Jan 1;164(1):5-8.

19.

Different cell surface oligomeric states of B7-1 and B7-2: implications for signaling.

Bhatia S, Edidin M, Almo SC, Nathenson SG.

Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15569-74. Epub 2005 Oct 12.

20.

Differential requirement for CD28/CTLA-4-CD80/CD86 interactions in drug-induced type 1 and type 2 immune responses to trinitrophenyl-ovalbumin.

Nierkens S, Aalbers M, Bol M, Bleumink R, van Kooten P, Boon L, Pieters R.

J Immunol. 2005 Sep 15;175(6):3707-14.

Supplemental Content

Support Center